REC-3565 (MALT1 inhibitor)
Recursion (trial sponsor Exscientia AI Ltd, a Recursion subsidiary): company profile
Phase 1 registry
Since , the date of the source that reports this phase.
Summary
REC-3565 is a MALT1 inhibitor from Recursion (trial sponsor Exscientia AI Ltd, a Recursion subsidiary). The source describes it as small molecule. It is being developed for relapsed or refractory B-cell malignancies, including CLL/SLL and Waldenström's macroglobulinemia. ClinicalTrials.gov lists it at Phase 1 (recruiting) under NCT06980116. The AI role named in the source is molecule design. Registry records: NCT06980116, Phase 1, recruiting, updated Aug 13, 2026. About the company, based in United States: Recursion OS pairs automated phenomic and other high-content biology at scale with machine learning, and since the November 2024 Exscientia combination also includes Exscientia's precision chemistry design. First patient dosed. The latest dated source is from Apr 8, 2025.
Built only from the sources listed on this page.
Facts
- Company
- Recursion (trial sponsor Exscientia AI Ltd, a Recursion subsidiary)
- Indication
- Relapsed or refractory B-cell malignancies, including CLL/SLL and Waldenström's macroglobulinemia
- Therapeutic area
- Oncology
- Modality
- Small molecule
- AI role
- Molecule design
- Phase in the source
- Phase 1, as of Apr 8, 2025
- Phase source
- Registry
- Board column
- Phase 1
Key readouts in the source
First patient dosed
AI evidence
AI source: Company
“REC-3565 is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor designed using Recursion’s AI-driven multi-parameter optimization approach.”
Trial records
- NCT06980116 on ClinicalTrials.gov (opens in new tab) Phase 1 Recruiting Updated
Milestone timeline
-
Official X post: Phase 1
First patient dosed
-
NCT06980116 record updated
Phase 1, Recruiting
-
Registry check
REC-3565 registered as EXS73565 (MALT1, Exscientia/Recursion).
About Recursion Pharmaceuticals
Recursion OS pairs automated phenomic and other high-content biology at scale with machine learning, and since the November 2024 Exscientia combination also includes Exscientia's precision chemistry design.
Spot an error? Tell me and I'll fix it.